Checkpoint Therapeutics, Inc (CKPT): Analyst Consensus Forecast
Checkpoint Therapeutics is developing budget-friendly immunotherapy methods by optimizing development costs to compete with major brands. The business model relies on outsourcing molecule synthesis and testing to external contractors, which creates a dependency on partners, and the indicator is 4.45. This chart on GURU.Markets complements data regarding the strict control of biomaterial delivery via verified express carriers.
Analytical breakdowns for Checkpoint Therapeutics, Inc (CKPT)
- market price and analyst price targets:
- stock exchange capitalization data:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Checkpoint Therapeutics|CKPT - Long-Term Debt to Capital|Short-Term Debt to Capital Checkpoint Therapeutics Inc|CKPT - Company Debts|Debt to Book Value Ratio Checkpoint Therapeutics, Inc|CKPT - Company Long-Term Debts|Company Current Liabilities Checkpoint Therapeutics|Immediate Liquidity checkpointtx.com
- earnings and valuation multiples indicators:
CKPT - Company Net Income|Expected Net Income Checkpoint Therapeutics|CKPT - Price to Earnings Ratio|Future Price to Earnings Multiple Checkpoint Therapeutics Inc.|CKPT - PEG Multiple|Enterprise Value to EBITDA Ratio Checkpoint Therapeutics, Inc|CKPT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Checkpoint Therapeutics|CKPT - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months checkpointtx.com|CKPT - Earnings growth in current year|Expected net earnings per share growth next year Checkpoint Therapeutics
Fundamental company analysis:checkpointtx.com (CKPT)
The prospects for Checkpoint Therapeutics (CKPT) depend on FDA approval of cosibelimab and potential M&A deals, rendering the share price sensitive to the interpretation of clinical data. This indicator aggregates investment house expectations, capturing the transformation of the business's fair value during periods of uncertainty; therefore, the history of expert consensus estimates serves as a filter to avoid purchasing assets based on false market impulses.
Competing companies
Consensus Target beigene.com ONC|Price Target Chart Halozyme HALO|Analyst Consensus Forecast Revolution Medicines Inc RVMD|AAPG - Price Target Chart|Forecast Levels Chart CGON|URGN (UroGen Pharma Ltd.) - Consensus Target|BCAX: Analyst Forecast Prices|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|Accuray - Analyst Consensus Forecast|SELLAS Life Sciences (SLS) - Consensus Target|ACTU: Analyst Consensus Forecast|Average Forecast Price Citius Oncology Inc (CTOR)|Price Target Chart TuHURA Biosciences Inc.|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics)|WHWK (aadibio.com) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics, Inc.)|CSBR - Consensus Target|XBIT: Consensus Target|CVM - Analyst Consensus Forecast|OS Therapies (OSTX) - Price Target Chart|Radiopharm Theranostics Ltd - Fair Value Consensus|ARTV (Artiva Biotherapeutics Inc.) - Analyst Consensus Forecast|Average Forecast Price Adlai Nortye Limited ANL|Analyst Consensus Forecast VERU|Consensus Target tempesttx.com TPST|Analyst Consensus Forecast XLO (Xilio Therapeutics)|Fair Value Consensus RENB|Mural Bio - Analyst Consensus Forecast|Average Forecast Price Kairos Pharma Ltd|OKUR: Analyst Consensus Forecast|Consensus Target CytoMed Therapeutics Limited|Price Target Chart Curis Inc.|Analyst Consensus Forecast Apollomics Corp|Price Target Chart Tharimmune Corp (THAR)|ADVB: Forecast Levels Chart|Price Target Chart Genprex, Inc. GNPX|Calidi Biotherapeutics Inc. (CLDI) - Average Forecast Price|Sunshine Biopharma - Analyst Consensus Forecast|Analyst Median Target Xenetic Biosciences XBIO|Salarius (SLRX) - Price Target Chart|Broker Consensus Forecast PPBT|Consensus Target AONC|BGNE (beigene.com) - Analyst Forecast Prices|Consensus Target ELEV (Elevation Oncology, Inc.)|ICAD (icadmed.com) - Fair Value Consensus|Ikena Oncology - Consensus Target|Analyst Forecast Prices NTBL (Notable Labs Corp)|Viracta - Analyst Consensus Forecast|Fair Value Consensus MOR (morphosys.com)|NAYA: Analyst Consensus Forecast|Average Forecast Price Ascentage Pharma Group International (AAPGV)
